ATOS
Price
$2.03Alerts
Change
-$0.11 (-5.14%)
Updated
Nov 11 closing price
Capitalization
21.16M
139 days until earnings call
Intraday BUY SELL Signals
RCKT
Price
$2.48Alerts
Change
+$0.03 (+1.22%)
Updated
Nov 11 closing price
Capitalization
261.81M
Earnings call today
Intraday BUY SELL Signals
Interact to see
Advertisement

ATOS vs RCKT

ATOS vs RCKT Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ATOS vs. RCKT commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATOS is a Hold and RCKT is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ATOS with price predictions
Nov 11, 2026

Aroon Indicator for ATOS shows an upward move is likely

ATOS's Aroon Indicator triggered a bullish signal on October 26, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 148 similar instances where the Aroon Indicator showed a similar pattern. In 120 of the 148 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 81%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +0.94% 3-day Advance, the price is estimated to grow further. Considering data from situations where ATOS advanced for three days, in 184 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

Bearish Trend Analysis

The 10-day RSI Indicator for ATOS moved out of overbought territory on October 19, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 22 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 73%.

The Momentum Indicator moved below the 0 level on October 27, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ATOS as a result. In 78 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.

The Moving Average Convergence Divergence Histogram (MACD) for ATOS turned negative on October 27, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 45 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.

ATOS moved below its 50-day moving average on October 27, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ATOS crossed bearishly below the 50-day moving average on November 03, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 76%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ATOS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.789) is normal, around the industry mean (3.498). P/E Ratio (-0.488) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. ATOS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATOS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for RCKT with price predictions
Nov 11, 2026

RCKT in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 16, 2026

RCKT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 32 of 39 cases where RCKT's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 82%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where RCKT's RSI Oscillator exited the oversold zone, 31 of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.

The Moving Average Convergence Divergence (MACD) for RCKT just turned positive on October 20, 2026. Looking at past instances where RCKT's MACD turned positive, the stock continued to rise in 41 of 50 cases over the following month. The odds of a continued upward trend are 82%.

Following a +5.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where RCKT advanced for three days, in 201 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 50 of 58 cases where RCKT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 86%.

The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RCKT as a result. In 71 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RCKT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

The Aroon Indicator for RCKT entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.710) is normal, around the industry mean (3.498). P/E Ratio (-14.906) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. RCKT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RCKT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
ATOS vs RCKT: Fundamental Ratings
ATOS
RCKT
OUTLOOK RATING
1..100
7016
VALUATION
overvalued / fair valued / undervalued
1..100
53
Fair valued
11
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9892
PRICE GROWTH RATING
1..100
8173
P/E GROWTH RATING
1..100
2715
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RCKT's Valuation (11) in the Biotechnology industry is somewhat better than the same rating for ATOS (53) in the Medical Specialties industry. This means that RCKT’s stock grew somewhat faster than ATOS’s over the last 12 months.

RCKT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ATOS (100) in the Medical Specialties industry. This means that RCKT’s stock grew similarly to ATOS’s over the last 12 months.

RCKT's SMR Rating (92) in the Biotechnology industry is in the same range as ATOS (98) in the Medical Specialties industry. This means that RCKT’s stock grew similarly to ATOS’s over the last 12 months.

RCKT's Price Growth Rating (73) in the Biotechnology industry is in the same range as ATOS (81) in the Medical Specialties industry. This means that RCKT’s stock grew similarly to ATOS’s over the last 12 months.

RCKT's P/E Growth Rating (15) in the Biotechnology industry is in the same range as ATOS (27) in the Medical Specialties industry. This means that RCKT’s stock grew similarly to ATOS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATOSRCKT
RSI
ODDS (%)
Bearish Trend 1 day ago
73%
Bullish Trend 1 day ago
79%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
86%
Momentum
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
89%
MACD
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
82%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
86%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
79%
Advances
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 8 days ago
80%
Declines
ODDS (%)
Bearish Trend 7 days ago
87%
Bearish Trend 6 days ago
87%
BollingerBands
ODDS (%)
N/A
Bullish Trend 1 day ago
82%
Aroon
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
90%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (ATOS: $2.14 vs. RCKT: $2.48)
Brand notoriety: ATOS and RCKT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATOS: 90% vs. RCKT: 48%
Market capitalization -- ATOS: $21.16M vs. RCKT: $261.81M
ATOS [@Biotechnology] is valued at $21.16M. RCKT’s [@Biotechnology] market capitalization is $261.81M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATOS’s FA Score shows that 1 FA rating(s) are green while RCKT’s FA Score has 2 green FA rating(s).

  • ATOS’s FA Score: 1 green, 4 red.
  • RCKT’s FA Score: 2 green, 3 red.
According to our system of comparison, RCKT is a better buy in the long-term than ATOS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATOS’s TA Score shows that 3 TA indicator(s) are bullish while RCKT’s TA Score has 4 bullish TA indicator(s).

  • ATOS’s TA Score: 3 bullish, 6 bearish.
  • RCKT’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, RCKT is a better buy in the short-term than ATOS.

Price Growth

ATOS (@Biotechnology) experienced а -8.15% price change this week, while RCKT (@Biotechnology) price change was -4.98% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.

Reported Earning Dates

ATOS is expected to report earnings on Nov 11, 2026.

RCKT is expected to report earnings on Nov 12, 2026.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

ATOS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATOS has been loosely correlated with AXON. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if ATOS jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATOS
1D Price
Change %
ATOS100%
-5.14%
AXON - ATOS
42%
Loosely correlated
+4.26%
AKBA - ATOS
36%
Loosely correlated
+5.89%
RARE - ATOS
35%
Loosely correlated
+3.47%
RCKT - ATOS
34%
Loosely correlated
+1.22%
ARRY - ATOS
34%
Loosely correlated
+9.94%
More

RCKT and

Correlation & Price change

A.I.dvisor indicates that over the last year, RCKT has been loosely correlated with SANA. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if RCKT jumps, then SANA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RCKT
1D Price
Change %
RCKT100%
+1.22%
SANA - RCKT
56%
Loosely correlated
-5.76%
EDIT - RCKT
56%
Loosely correlated
-4.99%
DYN - RCKT
55%
Loosely correlated
+0.39%
FDMT - RCKT
55%
Loosely correlated
+4.25%
SLDB - RCKT
55%
Loosely correlated
+6.00%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SMPL12.640.22
+1.77%
Simply Good Foods Company (The)
BSX45.130.43
+0.96%
Boston Scientific Corp
NWE84.970.05
+0.06%
NorthWestern Energy Group
RNAC6.88-0.01
-0.15%
Cartesian Therapeutics
KUST3.13-0.15
-4.57%
Kustom Entertainment Inc.